Author: Ravi Shankar

Receiving this honor for the seventh time is a reflection of the Bank’s culture and commitment to its people

ROCKVILLE, Md., Nov. 13, 2026 (GLOBE NEWSWIRE) — Capital Bank, N.A. has been named one of the Best Banks to Work For by American Banker for the seventh time. American Banker develops its annual ranking in partnership with Best Companies Group—an independent research firm that examines companies’ practices, programs, and benefits as well as surveys its employees for their perspective. Best Companies Group then uses this data to rank companies in industry-specific categories.

Every year, American Banker recognizes banks that excel at creating positive, supportive, and high-performing workplace cultures. Of the many that were considered, 100 banks earned a spot in the ranking of Best Banks to Work For in 2026.

“As a people-centric institution, our culture is rooted in employee-success,” said Eric Suss, Executive Vice President and Chief Human Resources Officer at Capital Bank. “Maintaining an environment that fosters creativity and determination is what keeps our employees engaged and energized.”

Capital Bank prioritizes employee well-being and career advancement opportunities through initiatives focused on rewarding excellence, promoting health and wellness, and encouraging community involvement. These efforts have granted employees meaningful opportunities to learn, contribute, and connect.

“By investing in our employees with programs that aim to enhance their skillsets, foster collaboration, and recognize exceptional work, we’re able to recruit and maintain top talent,” said Steven Poynot, Chief Executive Officer and President of Capital Bank. “Being named one of the Best Banks to Work For is a reflection of our commitment to our employees.”

To be considered for this honor, banks must have been in operation for a minimum of one year and employe at least 50 within the U.S. Best Companies Group manages the registration, survey process, and data analysis to determine the final rankings.

About Capital Bank

Capital Bank has been providing exceptional banking services since its inception in 1999. With over 25 years of experience, we have grown into a publicly traded company with $3.8 billion in assets as of 9/30/2026 (NASDAQ: CBNK). At Capital Bank, we pride ourselves on banking on human potential. Our commitment to human-centric banking has allowed us to make sound banking decisions based on factors beyond just what is on paper. As a member of the Federal Reserve Bank system, Member FDIC, and Equal Housing Lender, we are committed to helping our customers achieve their goals while upholding our fiduciary duty to our shareholders. 

CONTACT INFORMATION:

Capital Bank Media Relations & Communications 
Manager, Amber Logan
media.relations@capitalbankmd.com

Receiving this honor for the seventh time is a reflection of the Bank’s culture and commitment to its people

ROCKVILLE, Md., Nov. 13, 2026 (GLOBE NEWSWIRE) — Capital Bank, N.A. has been named one of the Best Banks to Work For by American Banker for the seventh time. American Banker develops its annual ranking in partnership with Best Companies Group—an independent research firm that examines companies’ practices, programs, and benefits as well as surveys its employees for their perspective. Best Companies Group then uses this data to rank companies in industry-specific categories.

Every year, American Banker recognizes banks that excel at creating positive, supportive, and high-performing workplace cultures. Of the many that were considered, 100 banks earned a spot in the ranking of Best Banks to Work For in 2026.

“As a people-centric institution, our culture is rooted in employee-success,” said Eric Suss, Executive Vice President and Chief Human Resources Officer at Capital Bank. “Maintaining an environment that fosters creativity and determination is what keeps our employees engaged and energized.”

Capital Bank prioritizes employee well-being and career advancement opportunities through initiatives focused on rewarding excellence, promoting health and wellness, and encouraging community involvement. These efforts have granted employees meaningful opportunities to learn, contribute, and connect.

“By investing in our employees with programs that aim to enhance their skillsets, foster collaboration, and recognize exceptional work, we’re able to recruit and maintain top talent,” said Steven Poynot, Chief Executive Officer and President of Capital Bank. “Being named one of the Best Banks to Work For is a reflection of our commitment to our employees.”

To be considered for this honor, banks must have been in operation for a minimum of one year and employe at least 50 within the U.S. Best Companies Group manages the registration, survey process, and data analysis to determine the final rankings.

About Capital Bank

Capital Bank has been providing exceptional banking services since its inception in 1999. With over 25 years of experience, we have grown into a publicly traded company with $3.8 billion in assets as of 9/30/2026 (NASDAQ: CBNK). At Capital Bank, we pride ourselves on banking on human potential. Our commitment to human-centric banking has allowed us to make sound banking decisions based on factors beyond just what is on paper. As a member of the Federal Reserve Bank system, Member FDIC, and Equal Housing Lender, we are committed to helping our customers achieve their goals while upholding our fiduciary duty to our shareholders. 

CONTACT INFORMATION:

Capital Bank Media Relations & Communications 
Manager, Amber Logan
media.relations@capitalbankmd.com

Luxembourg – 13 November 2026 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced a sizeable¹ contract award from Kosmos Energy Gulf of Mexico Operations, LLC, for the Tiberius Project² in the US Gulf. The development is located in lease KC-964 at a water depth of approximately 2,200 metres.

The scope of work covers the fabrication, transportation, and installation of a 14-kilometre steel catenary riser and wet-insulated flowline to the Lucius Spar, along with the installation of an umbilical and subsea controls.

Project management and engineering will begin in the coming months at Subsea7’s Houston, Texas, office. Offshore activities are expected to start in 2028.

Craig Broussard, Senior Vice President for Subsea7 US, said, “We are proud to work with Kosmos on this deepwater tieback. Drawing on our deepwater expertise and a closely aligned, collaborative approach, we have developed a cost-effective solution designed to support safe and efficient delivery.”

(1) Subsea7 defines a sizeable contract as being between $50 million and $150 million.
(2) Kosmos 33.34%, Occidental 33.33%, Navitas Petroleum US, LLC 33.33%

*******************************************************************************

Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry, creating sustainable value by being the industry’s partner and employer of choice in delivering the efficient offshore solutions the world needs.

Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.

*******************************************************************************

Contact for investment community enquiries:
Katherine Tonks
Investor Relations Director
Tel +44 20 8210 5568
ir@subsea7.com

Contact for media enquiries:
Ashley Shearer
Communications Manager
Tel +1 713 300 6792
ashley.shearer@subsea7.com

Forward-Looking Statements: This document may contain ‘forward-looking statements’ (within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995). These statements relate to our current expectations, beliefs, intentions, assumptions or strategies regarding the future and are subject to known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements may be identified by the use of words such as ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘future’, ‘goal’, ‘intend’, ‘likely’ ‘may’, ‘plan’, ‘project’, ‘seek’, ‘should’, ‘strategy’ ‘will’, and similar expressions. The principal risks which could affect future operations of the Group are described in the ‘Risk Management’ section of the Group’s Annual Report and Consolidated Financial Statements. Factors that may cause actual and future results and trends to differ materially from our forward-looking statements include (but are not limited to): (i) our ability to deliver fixed price projects in accordance with client expectations and within the parameters of our bids, and to avoid cost overruns; (ii) our ability to collect receivables, negotiate variation orders and collect the related revenue; (iii) our ability to recover costs on significant projects; (iv) capital expenditure by oil and gas companies, which is affected by fluctuations in the price of, and demand for, crude oil and natural gas; (v) unanticipated delays or cancellation of projects included in our backlog; (vi) competition and price fluctuations in the markets and businesses in which we operate; (vii) the loss of, or deterioration in our relationship with, any significant clients; (viii) the outcome of legal proceedings or governmental inquiries; (ix) uncertainties inherent in operating internationally, including economic, political and social instability, boycotts or embargoes, labour unrest, changes in foreign governmental regulations, corruption and currency fluctuations; (x) the effects of a pandemic or epidemic or a natural disaster; (xi) liability to third parties for the failure of our joint venture partners to fulfil their obligations; (xii) changes in, or our failure to comply with, applicable laws and regulations (including regulatory measures addressing climate change); (xiii) operating hazards, including spills, environmental damage, personal or property damage and business interruptions caused by adverse weather; (xiv) equipment or mechanical failures, which could increase costs, impair revenue and result in penalties for failure to meet project completion requirements; (xv) the timely delivery of vessels on order and the timely completion of ship conversion programmes; (xvi) our ability to keep pace with technological changes and the impact of potential information technology, cyber security or data security breaches; (xvii) global availability at scale and commercially viability of suitable alternative vessel fuels; and (xviii) the effectiveness of our disclosure controls and procedures and internal control over financial reporting. Many of these factors are beyond our ability to control or predict. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Each forward-looking statement speaks only as of the date of this document. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 13 November 2026 at 19:40 CET.

Attachment

• SUBC Tiberius

Luxembourg – 13 November 2026 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced a sizeable¹ contract award from Kosmos Energy Gulf of Mexico Operations, LLC, for the Tiberius Project² in the US Gulf. The development is located in lease KC-964 at a water depth of approximately 2,200 metres.

The scope of work covers the fabrication, transportation, and installation of a 14-kilometre steel catenary riser and wet-insulated flowline to the Lucius Spar, along with the installation of an umbilical and subsea controls.

Project management and engineering will begin in the coming months at Subsea7’s Houston, Texas, office. Offshore activities are expected to start in 2028.

Craig Broussard, Senior Vice President for Subsea7 US, said, “We are proud to work with Kosmos on this deepwater tieback. Drawing on our deepwater expertise and a closely aligned, collaborative approach, we have developed a cost-effective solution designed to support safe and efficient delivery.”

(1) Subsea7 defines a sizeable contract as being between $50 million and $150 million.
(2) Kosmos 33.34%, Occidental 33.33%, Navitas Petroleum US, LLC 33.33%

*******************************************************************************

Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry, creating sustainable value by being the industry’s partner and employer of choice in delivering the efficient offshore solutions the world needs.

Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.

*******************************************************************************

Contact for investment community enquiries:
Katherine Tonks
Investor Relations Director
Tel +44 20 8210 5568
ir@subsea7.com

Contact for media enquiries:
Ashley Shearer
Communications Manager
Tel +1 713 300 6792
ashley.shearer@subsea7.com

Forward-Looking Statements: This document may contain ‘forward-looking statements’ (within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995). These statements relate to our current expectations, beliefs, intentions, assumptions or strategies regarding the future and are subject to known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements may be identified by the use of words such as ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘future’, ‘goal’, ‘intend’, ‘likely’ ‘may’, ‘plan’, ‘project’, ‘seek’, ‘should’, ‘strategy’ ‘will’, and similar expressions. The principal risks which could affect future operations of the Group are described in the ‘Risk Management’ section of the Group’s Annual Report and Consolidated Financial Statements. Factors that may cause actual and future results and trends to differ materially from our forward-looking statements include (but are not limited to): (i) our ability to deliver fixed price projects in accordance with client expectations and within the parameters of our bids, and to avoid cost overruns; (ii) our ability to collect receivables, negotiate variation orders and collect the related revenue; (iii) our ability to recover costs on significant projects; (iv) capital expenditure by oil and gas companies, which is affected by fluctuations in the price of, and demand for, crude oil and natural gas; (v) unanticipated delays or cancellation of projects included in our backlog; (vi) competition and price fluctuations in the markets and businesses in which we operate; (vii) the loss of, or deterioration in our relationship with, any significant clients; (viii) the outcome of legal proceedings or governmental inquiries; (ix) uncertainties inherent in operating internationally, including economic, political and social instability, boycotts or embargoes, labour unrest, changes in foreign governmental regulations, corruption and currency fluctuations; (x) the effects of a pandemic or epidemic or a natural disaster; (xi) liability to third parties for the failure of our joint venture partners to fulfil their obligations; (xii) changes in, or our failure to comply with, applicable laws and regulations (including regulatory measures addressing climate change); (xiii) operating hazards, including spills, environmental damage, personal or property damage and business interruptions caused by adverse weather; (xiv) equipment or mechanical failures, which could increase costs, impair revenue and result in penalties for failure to meet project completion requirements; (xv) the timely delivery of vessels on order and the timely completion of ship conversion programmes; (xvi) our ability to keep pace with technological changes and the impact of potential information technology, cyber security or data security breaches; (xvii) global availability at scale and commercially viability of suitable alternative vessel fuels; and (xviii) the effectiveness of our disclosure controls and procedures and internal control over financial reporting. Many of these factors are beyond our ability to control or predict. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Each forward-looking statement speaks only as of the date of this document. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 13 November 2026 at 19:40 CET.

Attachment

• SUBC Tiberius

• If approved, Cosentyx^® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe^1,2
• HS affects as many as one in 100 people worldwide,³ with more than half developing symptoms during adolescence4,5

Basel, November 13, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of Cosentyx^® (secukinumab) for adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic HS therapy.⁶ If approved by the European Commission (EC), Cosentyx would become the only interleukin-17A (IL-17A) inhibitor approved for adolescent HS in Europe and the first innovative biologic treatment option for this population in nearly a decade, addressing a significant unmet need where treatment options remain limited.^1,2,7,8

HS is a chronic, systemic, progressive and often painful inflammatory skin disease.^5,9 It causes recurring boil-like abscesses that can burst, creating open wounds, often in the most intimate parts of the body, which may result in irreversible scarring.^5,8-10 More than 50% of cases begin during puberty.^4,5

“Hidradenitis suppurativa often begins during adolescence, a critical period when the disease can progress to irreversible scarring, yet we currently have limited treatment options for this age group,” said Dr. John Ingram, Clinical Professor, Cardiff University School of Medicine, United Kingdom. “This positive CHMP opinion for secukinumab represents an important step toward addressing a meaningful gap in care for young people living with this challenging disease.”

The CHMP positive opinion is based on evidence demonstrating that weight-based dosing in adolescents aged 12 years and older provides Cosentyx exposure generally comparable to that observed in adults with HS.² This includes efficacy and safety data from adult HS clinical studies, pharmacokinetic modeling extrapolated from adult HS and psoriasis clinical trials, pediatric clinical trial data from other approved Cosentyx indications, and weight-based dosing analyses.^2,11–14 The safety profile of Cosentyx is well-established across several approved adult and pediatric indications.^2,15-17

“For over a decade, Cosentyx has helped transform outcomes across several immune-mediated diseases, including hidradenitis suppurativa. Adolescents living with moderate to severe HS deserve access to more advanced treatment options,” said Patrick Horber, President, International, Novartis. “This positive CHMP opinion brings us closer to that goal in Europe, and we look forward to the European Commission decision in the coming months.”

The EC is expected to issue a final decision within approximately two months, following today’s CHMP opinion.

About Cosentyx
Cosentyx is a fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation underlying multiple immune-mediated inflammatory diseases.^18,19 It is approved for use in adults with psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), hidradenitis suppurativa (HS), and polymyalgia rheumatica (PMR).^2,19–21 Cosentyx is also approved for use in pediatric patients, including those with PsO, juvenile idiopathic arthritis subtypes such as juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), and in the U.S. for pediatric patients aged 12 years and older with moderate to severe HS and for juvenile AS.^{2,12-14,19,22,23}

About Novartis in Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with complex, and often overlooked autoimmune and other immune-mediated diseases, so they can reclaim their lives. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. European Medicines Agency. Search results for “hidradenitis suppurativa.” European Medicines Agency. https://www.ema.europa.eu/en/search?search_api_fulltext=polymyalgia%20rheumatica&keywords=allwords&keyword=hidradenitis%20suppurativa%20&f%5B0%5D=is_document%3ADocument&page=0  [Last Accessed: November 2026]. 
2. Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf [Last Accessed: November 2026].
3. MedLine Plus. Hidradenitis suppurativa [online]. Available from: https://medlineplus.gov/genetics/condition/hidradenitis-suppurativa/ [Last accessed: November 2026].  
4. Molina-Leyva A, Cuenca-Barrales C. Adolescent-onset hidradenitis suppurativa: prevalence, risk factors and disease features. Dermatology. 2019;235(1):45-50. doi:10.1159/000493465  
5. Hallock KK, Mizerak MR, Dempsey A, Maczuga S, Kirby JS. Differences between children and adults with hidradenitis suppurativa. JAMA Dermatol. 2021;157(9):1095-1101. doi:10.1001/jamadermatol.2021.2865  
6. European Medicines Agency (EMA). Cosentyx, INN-secukinumab: CHMP post-authorisation summary of positive opinion. European Medicines Agency; 2026. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-vr-0000340032_en.pdf. [Last Accessed November 13, 2026]
7. AbbVie. AbbVie’s HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease. Available at: https://news.abbvie.com/2016-11-14-AbbVies-HUMIRA-Adalimumab-Receives-CHMP-Positive-Opinion-to-Treat-Adolescents-with-Hidradenitis-Suppurativa-a-Chronic-Inflammatory-Skin-Disease [Last Accessed: November 2026].
8. European Medicines Agency. Biosimilar medicines: Overview. Available at: https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview [Last Accessed: November 2026]. 
9. Garg A, Naik HB, Alavi A, et al. Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data. Dermatol Ther (Heidelb). 2023 Feb;13(2):581-594. doi: 10.1007/s13555-022-00872-1.
10. Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers 2020; 6: 18.
11. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 2023; 401: 747-761. 
12. Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis [Last Accessed: November 2026]. 
13. Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis [Last Accessed: November 2026]. 
14. Novartis Cosentyx receives positive CHMP opinion for expanded use in childhood arthritic conditions. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions [Last Accessed: November 2026]. 
15. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S. “Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5-Year Efficacy and Safety Results from a Phase 3 Trial”. ACR/ARHP 2020 Annual Meeting Abstract. Presented in ACR Open Rheumatology (2020); CONCL00511. 
16. McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG, Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L, Mpofu S; FUTURE 2 Study Group. “Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end of study) results from the phase III FUTURE 2 study.” Lancet Rheumatology. 2020; 2(4): e227–e235. 
17. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507–1514. 
18. Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa. Available at: https://www.novartis.com/news/media-releases/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa [Last accessed: November 2026].
19. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717–724.  
20. Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials [Last Accessed: November 2026]. 
21. Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR). [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-cosentyx-polymyalgia-rheumatica-pmr [Last Accessed: November 2026].
22. Novartis. Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa [Last Accessed: November 2026].
23. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf [Last Accessed: November 2026].

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

• If approved, Cosentyx^® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe^1,2
• HS affects as many as one in 100 people worldwide,³ with more than half developing symptoms during adolescence4,5

Basel, November 13, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of Cosentyx^® (secukinumab) for adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic HS therapy.⁶ If approved by the European Commission (EC), Cosentyx would become the only interleukin-17A (IL-17A) inhibitor approved for adolescent HS in Europe and the first innovative biologic treatment option for this population in nearly a decade, addressing a significant unmet need where treatment options remain limited.^1,2,7,8

HS is a chronic, systemic, progressive and often painful inflammatory skin disease.^5,9 It causes recurring boil-like abscesses that can burst, creating open wounds, often in the most intimate parts of the body, which may result in irreversible scarring.^5,8-10 More than 50% of cases begin during puberty.^4,5

“Hidradenitis suppurativa often begins during adolescence, a critical period when the disease can progress to irreversible scarring, yet we currently have limited treatment options for this age group,” said Dr. John Ingram, Clinical Professor, Cardiff University School of Medicine, United Kingdom. “This positive CHMP opinion for secukinumab represents an important step toward addressing a meaningful gap in care for young people living with this challenging disease.”

The CHMP positive opinion is based on evidence demonstrating that weight-based dosing in adolescents aged 12 years and older provides Cosentyx exposure generally comparable to that observed in adults with HS.² This includes efficacy and safety data from adult HS clinical studies, pharmacokinetic modeling extrapolated from adult HS and psoriasis clinical trials, pediatric clinical trial data from other approved Cosentyx indications, and weight-based dosing analyses.^2,11–14 The safety profile of Cosentyx is well-established across several approved adult and pediatric indications.^2,15-17

“For over a decade, Cosentyx has helped transform outcomes across several immune-mediated diseases, including hidradenitis suppurativa. Adolescents living with moderate to severe HS deserve access to more advanced treatment options,” said Patrick Horber, President, International, Novartis. “This positive CHMP opinion brings us closer to that goal in Europe, and we look forward to the European Commission decision in the coming months.”

The EC is expected to issue a final decision within approximately two months, following today’s CHMP opinion.

About Cosentyx
Cosentyx is a fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation underlying multiple immune-mediated inflammatory diseases.^18,19 It is approved for use in adults with psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), hidradenitis suppurativa (HS), and polymyalgia rheumatica (PMR).^2,19–21 Cosentyx is also approved for use in pediatric patients, including those with PsO, juvenile idiopathic arthritis subtypes such as juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), and in the U.S. for pediatric patients aged 12 years and older with moderate to severe HS and for juvenile AS.^{2,12-14,19,22,23}

About Novartis in Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with complex, and often overlooked autoimmune and other immune-mediated diseases, so they can reclaim their lives. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. European Medicines Agency. Search results for “hidradenitis suppurativa.” European Medicines Agency. https://www.ema.europa.eu/en/search?search_api_fulltext=polymyalgia%20rheumatica&keywords=allwords&keyword=hidradenitis%20suppurativa%20&f%5B0%5D=is_document%3ADocument&page=0  [Last Accessed: November 2026]. 
2. Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf [Last Accessed: November 2026].
3. MedLine Plus. Hidradenitis suppurativa [online]. Available from: https://medlineplus.gov/genetics/condition/hidradenitis-suppurativa/ [Last accessed: November 2026].  
4. Molina-Leyva A, Cuenca-Barrales C. Adolescent-onset hidradenitis suppurativa: prevalence, risk factors and disease features. Dermatology. 2019;235(1):45-50. doi:10.1159/000493465  
5. Hallock KK, Mizerak MR, Dempsey A, Maczuga S, Kirby JS. Differences between children and adults with hidradenitis suppurativa. JAMA Dermatol. 2021;157(9):1095-1101. doi:10.1001/jamadermatol.2021.2865  
6. European Medicines Agency (EMA). Cosentyx, INN-secukinumab: CHMP post-authorisation summary of positive opinion. European Medicines Agency; 2026. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-vr-0000340032_en.pdf. [Last Accessed November 13, 2026]
7. AbbVie. AbbVie’s HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease. Available at: https://news.abbvie.com/2016-11-14-AbbVies-HUMIRA-Adalimumab-Receives-CHMP-Positive-Opinion-to-Treat-Adolescents-with-Hidradenitis-Suppurativa-a-Chronic-Inflammatory-Skin-Disease [Last Accessed: November 2026].
8. European Medicines Agency. Biosimilar medicines: Overview. Available at: https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview [Last Accessed: November 2026]. 
9. Garg A, Naik HB, Alavi A, et al. Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims Data. Dermatol Ther (Heidelb). 2023 Feb;13(2):581-594. doi: 10.1007/s13555-022-00872-1.
10. Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers 2020; 6: 18.
11. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 2023; 401: 747-761. 
12. Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis [Last Accessed: November 2026]. 
13. Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis [Last Accessed: November 2026]. 
14. Novartis Cosentyx receives positive CHMP opinion for expanded use in childhood arthritic conditions. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions [Last Accessed: November 2026]. 
15. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S. “Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5-Year Efficacy and Safety Results from a Phase 3 Trial”. ACR/ARHP 2020 Annual Meeting Abstract. Presented in ACR Open Rheumatology (2020); CONCL00511. 
16. McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG, Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L, Mpofu S; FUTURE 2 Study Group. “Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end of study) results from the phase III FUTURE 2 study.” Lancet Rheumatology. 2020; 2(4): e227–e235. 
17. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R, Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507–1514. 
18. Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa. Available at: https://www.novartis.com/news/media-releases/novartis-receives-european-approval-cosentyx-first-and-only-il-17a-inhibitor-hidradenitis-suppurativa [Last accessed: November 2026].
19. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717–724.  
20. Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials [Last Accessed: November 2026]. 
21. Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR). [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-cosentyx-polymyalgia-rheumatica-pmr [Last Accessed: November 2026].
22. Novartis. Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa [Last Accessed: November 2026].
23. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf [Last Accessed: November 2026].

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

NEW YORK, NY, Nov. 13, 2026 (GLOBE NEWSWIRE) —  FACT II Acquisition Corp. (NASDAQ: FACT) (“FACT II” or the “Company”) said today that it intends to postpone its extraordinary general meeting of shareholders (the “Extension Meeting”).

The global technology outage over the past 24 hours has caused and continues to cause delays to normal business activity. As a result, the Company intends to postpone the Extension Meeting so that all shareholders have enough time to act according to their voting and extension intentions.

The meeting date will be postponed to Friday 20th November at a time to be confirmed, to vote on, among other things, the proposal to extend the date by which the Company must complete its initial business combination (the “Extension”). The new redemption  deadline will be Wednesday November 18th.

The Company will file a Form 8-K with the SEC as soon as possible today to confirm the postponement and the revised redemption deadline.

Contact

For any further enquires please contact FACT II Acquisition Corp. at ir@freedomac2.com

NEW YORK, NY, Nov. 13, 2026 (GLOBE NEWSWIRE) —  FACT II Acquisition Corp. (NASDAQ: FACT) (“FACT II” or the “Company”) said today that it intends to postpone its extraordinary general meeting of shareholders (the “Extension Meeting”).

The global technology outage over the past 24 hours has caused and continues to cause delays to normal business activity. As a result, the Company intends to postpone the Extension Meeting so that all shareholders have enough time to act according to their voting and extension intentions.

The meeting date will be postponed to Friday 20th November at a time to be confirmed, to vote on, among other things, the proposal to extend the date by which the Company must complete its initial business combination (the “Extension”). The new redemption  deadline will be Wednesday November 18th.

The Company will file a Form 8-K with the SEC as soon as possible today to confirm the postponement and the revised redemption deadline.

Contact

For any further enquires please contact FACT II Acquisition Corp. at ir@freedomac2.com

SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:

UBS Global Biopharma London Conference
November 17, 2026
1:20 p.m. GMT/ 8:20 a.m. ET / 5:20 a.m. PT

Jefferies Global Healthcare Conference
November 18, 2026
2:30 p.m. GMT/ 9:30 a.m. ET / 6:30 a.m. PT

Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following the events.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
gmann@kuraoncology.com

EAGLE, Idaho, Nov. 13, 2026 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it will participate in the upcoming 2026 Stephens Annual Investment Conference on November 17, 2026.

Lynette Walbom, Chief Financial Officer, and John Gochnour, President and Chief Operating Officer, will participate in a fireside chat on November 17, 2026 at 11:45 a.m. Central Time. A live webcast of the event will be accessible at the following address:
https://event.summitcast.com/view/AnJcL7fjsXraGqV8XG6fRL/guest_book?session_id=FeS4aU6vg6dnAHWN4SmCNi 

About Pennant^:

The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services located throughout Alabama, Arizona, California, Colorado, Georgia, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated “company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “its” and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity. More information about Pennant is available at www.pennantgroup.com.

Contact Information

The Pennant Group, Inc.
(208) 506-6100
ir@pennantgroup.com

SOURCE: The Pennant Group, Inc.